Li Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Li Zhu has a total of 325 co-authors. Here are the top co-authors by number of shared publications:
- Chao Wu
Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
13 shared publications - Chuanwu Zhu
Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow University, The Fifth People’s Hospital of Suzhou, China
12 shared publications Jian Wang
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China
10 shared publications- Rui Huang
Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
10 shared publications Jiacheng Liu
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
8 shared publicationsShengxia Yin
Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China
8 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1936616
YOD1 stabilizes HIV-1 Nef via K6-linked deubiquitination to promote viral infectivity and impair immune recovery
Background: Immune non-response to antiretroviral therapy remains a major challenge in HIV-1 management, yet the underlying molecular mechanisms are incompletely understood. Methods: In this study, we performed comparative quantitative proteomics on samples from immunonon-responsive (INR) and immune-responsive (IR) individuals, identifying the deubiquitinase YOD1 as one of the most significantly upregulated proteins in INR patients, accompanied by hyperactivation of ubiquitin‑proteasome pathways. Results: Through immunoprecipitation coupled with mass spectrometry, we found that YOD1 associates with the HIV-1 Nef protein, a key viral factor that subverts host immunity. Mechanistically, YOD1 specifically removes K6‑linked polyubiquitin chains from Nef via its catalytic cysteine residue (C155S), thereby preventing proteasomal degradation and dose‑dependently stabilizing Nef protein levels without affecting its transcription. This regulation was selective for Nef, as YOD1 did not alter other HIV‑1 proteins (gp120, Vif, or Tat). In HIV‑1‑infected THP‑1 macrophages and clinical PBMCs from people living with HIV, YOD1 expression correlated positively with Nef levels and viral load; knockdown or catalytic inactivation of YOD1 markedly increased Nef ubiquitination, reduced p24 antigen secretion, and suppressed virus production. Importantly, screening of nutritional compounds revealed that Vitamin C (VC) promotes YOD1 degradation via the ubiquitin‑proteasome pathway, leading to downregulation of Nef, inhibition of HIV‑1 replication, and restoration of CD4+ T‑cell counts. These antiviral and immune‑restorative effects of VC were completely abrogated upon YOD1 depletion, confirming their dependency on YOD1 targeting. Conclusion: Collectively, our findings establish YOD1 as a critical host factor that sustains HIV‑1 Nef stability and viral infectivity through K6‑linked deubiquitination, and they identify Vitamin C as a clinically accessible agent that degrades YOD1, offering a potential adjuvant strategy to improve immune recovery in non‑responding patients.
- 23 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1936616
Open AccessYOD1 stabilizes HIV-1 Nef via K6-linked deubiquitination to promote viral infectivity and impair immune recovery
Background: Immune non-response to antiretroviral therapy remains a major challenge in HIV-1 management, yet the underlying molecular mechanisms are incompletely understood. Methods: In this study, we performed comparative quantitative proteomics on samples from immunonon-responsive (INR) and immune-responsive (IR) individuals, identifying the deubiquitinase YOD1 as one of the most significantly upregulated proteins in INR patients, accompanied by hyperactivation of ubiquitin‑proteasome pathways. Results: Through immunoprecipitation coupled with mass spectrometry, we found that YOD1 associates with the HIV-1 Nef protein, a key viral factor that subverts host immunity. Mechanistically, YOD1 specifically removes K6‑linked polyubiquitin chains from Nef via its catalytic cysteine residue (C155S), thereby preventing proteasomal degradation and dose‑dependently stabilizing Nef protein levels without affecting its transcription. This regulation was selective for Nef, as YOD1 did not alter other HIV‑1 proteins (gp120, Vif, or Tat). In HIV‑1‑infected THP‑1 macrophages and clinical PBMCs from people living with HIV, YOD1 expression correlated positively with Nef levels and viral load; knockdown or catalytic inactivation of YOD1 markedly increased Nef ubiquitination, reduced p24 antigen secretion, and suppressed virus production. Importantly, screening of nutritional compounds revealed that Vitamin C (VC) promotes YOD1 degradation via the ubiquitin‑proteasome pathway, leading to downregulation of Nef, inhibition of HIV‑1 replication, and restoration of CD4+ T‑cell counts. These antiviral and immune‑restorative effects of VC were completely abrogated upon YOD1 depletion, confirming their dependency on YOD1 targeting. Conclusion: Collectively, our findings establish YOD1 as a critical host factor that sustains HIV‑1 Nef stability and viral infectivity through K6‑linked deubiquitination, and they identify Vitamin C as a clinically accessible agent that degrades YOD1, offering a potential adjuvant strategy to improve immune recovery in non‑responding patients.
- Open Access
- 20 August 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1818958
HBsAg glycan isomer: a potential circulating biomarker for monitoring cccDNA and predicting virologic response in chronic hepatitis B
Background: Previous research has identified that Hepatitis B surface antigen glycan isomer (HBsAgGi) specifically marks O-glycosylated M-HBsAg exclusively present on infectious Dane particles (unlike total HBsAg, which is dominated by non-infectious subviral particles), it offers a more specific association with infectious viral burden and cccDNA activity. Accordingly, the present study aims to assess the potential of HBsAgGi as a circulating biomarker to reflect intrahepatic covalently closed circular DNA (cccDNA) and transcriptional activity, and for monitoring antiviral response. Methods: A total of 73 individuals diagnosed with chronic genotype C HBV infection were recruited for this study. Serum concentrations of HBsAgGi, HBsAg, HBeAg, HBV DNA, and HBV RNA were measured. Intrahepatic cccDNA and HBV RNA loads were determined in liver biopsy specimens obtained from 16 patients. Correlations between serum HBsAgGi and intrahepatic markers were analyzed. We measured serum Hepatitis B core-related antigen (HBcrAg) levels in 28 patients. 18 patients received nucleos(t)ide analogue therapy for 48 weeks and we evaluated levels of HBsAgGi after therapy. Additionally, receiver operating characteristic (ROC) curve analysis was conducted to assess the discriminative ability of the candidate biomarkers in predicting virological response (VR). Results: Serum HBsAgGi demonstrated significant positive correlations with intrahepatic cccDNA (r = 0.7172, P < 0.01), HBV RNA (r = 0.7879, P < 0.01), and the RNA/cccDNA ratio (r = 0.5840, P < 0.05), showing stronger correlations than conventional serum markers (HBcrAg, HBV RNA, DNA, HBsAg). HBsAgGi also showed the strongest correlation with serum HBcrAg (r = 0.5361, P < 0.01) in 28 patients. During treatment, HBsAgGi levels declined and baseline HBsAgGi predicted VR with superior accuracy (AUC = 0.9538) versus other markers. Conclusion: Serum HBsAgGi represents an emerging, minimally invasive serum indicator for assessing intrahepatic cccDNA loads and viral transcriptional activity, demonstrating stronger correlations with intrahepatic markers compared to conventional serum markers in this cohort. It also shows promising utility for predicting treatment response.
- 20 August 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1818958
Open AccessHBsAg glycan isomer: a potential circulating biomarker for monitoring cccDNA and predicting virologic response in chronic hepatitis B
Background: Previous research has identified that Hepatitis B surface antigen glycan isomer (HBsAgGi) specifically marks O-glycosylated M-HBsAg exclusively present on infectious Dane particles (unlike total HBsAg, which is dominated by non-infectious subviral particles), it offers a more specific association with infectious viral burden and cccDNA activity. Accordingly, the present study aims to assess the potential of HBsAgGi as a circulating biomarker to reflect intrahepatic covalently closed circular DNA (cccDNA) and transcriptional activity, and for monitoring antiviral response. Methods: A total of 73 individuals diagnosed with chronic genotype C HBV infection were recruited for this study. Serum concentrations of HBsAgGi, HBsAg, HBeAg, HBV DNA, and HBV RNA were measured. Intrahepatic cccDNA and HBV RNA loads were determined in liver biopsy specimens obtained from 16 patients. Correlations between serum HBsAgGi and intrahepatic markers were analyzed. We measured serum Hepatitis B core-related antigen (HBcrAg) levels in 28 patients. 18 patients received nucleos(t)ide analogue therapy for 48 weeks and we evaluated levels of HBsAgGi after therapy. Additionally, receiver operating characteristic (ROC) curve analysis was conducted to assess the discriminative ability of the candidate biomarkers in predicting virological response (VR). Results: Serum HBsAgGi demonstrated significant positive correlations with intrahepatic cccDNA (r = 0.7172, P < 0.01), HBV RNA (r = 0.7879, P < 0.01), and the RNA/cccDNA ratio (r = 0.5840, P < 0.05), showing stronger correlations than conventional serum markers (HBcrAg, HBV RNA, DNA, HBsAg). HBsAgGi also showed the strongest correlation with serum HBcrAg (r = 0.5361, P < 0.01) in 28 patients. During treatment, HBsAgGi levels declined and baseline HBsAgGi predicted VR with superior accuracy (AUC = 0.9538) versus other markers. Conclusion: Serum HBsAgGi represents an emerging, minimally invasive serum indicator for assessing intrahepatic cccDNA loads and viral transcriptional activity, demonstrating stronger correlations with intrahepatic markers compared to conventional serum markers in this cohort. It also shows promising utility for predicting treatment response.
- Open Access
- 9 July 2026
- Published by Springer Nature in Immunity & Inflammation
- Vol. 2 (1) , 30
Hepatocyte-derived soluble Tim-3 contributes to alleviating acetaminophen-induced liver injury
- 9 July 2026
- Published by Springer Nature in Immunity & Inflammation
- Vol. 2 (1) , 30
Open AccessHepatocyte-derived soluble Tim-3 contributes to alleviating acetaminophen-induced liver injury
- Open Access
- 23 June 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (15) , e70288
Soluble B7 ‐ H6 as a Novel Diagnostic Biomarker for Post‐Hepatitis B Cirrhosis: A Clinical Value Study
Objective: This study aimed to assess the diagnostic value of soluble B7‐H6 (sB7‐H6) as a biomarker for post‐hepatitis B cirrhosis (LC) and to compare its performance with conventional non‐invasive biomarkers, including FIB‐4 and APRI. Methods: A prospective cohort study was conducted with 159 patients diagnosed with HBV‐related liver diseases, including 77 with chronic hepatitis B (CHB) and 82 with post‐hepatitis B cirrhosis (LC). Serum sB7‐H6 levels were quantified using enzyme‐linked immunosorbent assay (ELISA). The diagnostic performance of sB7‐H6 was evaluated through receiver operating characteristic (ROC) curve analysis. The diagnostic accuracy of sB7‐H6, both alone and in combination with FIB‐4, was compared to the traditional biomarkers APRI and FIB‐4. Results: Serum sB7‐H6 levels increased progressively with disease severity, with the highest levels observed in the LC group. The area under the ROC curve (AUC) for sB7‐H6 alone in diagnosing cirrhosis was 0.87, which was superior to both APRI (AUC = 0.75) and FIB‐4 (AUC = 0.79). The combined model of sB7‐H6 and FIB‐4 demonstrated improved diagnostic performance, achieving an AUC of 0.92, with sensitivity of 85.4% and specificity of 88.0%. Conclusion: Serum sB7‐H6 is a promising, non‐invasive biomarker for diagnosing post‐hepatitis B cirrhosis, outperforming traditional biomarkers such as FIB‐4 and APRI. The combined model of sB7‐H6 and FIB‐4 provides superior diagnostic accuracy and holds significant potential for clinical use in the early detection and risk stratification of liver cirrhosis in HBV‐infected patients.
- 23 June 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (15) , e70288
Open AccessSoluble B7 ‐ H6 as a Novel Diagnostic Biomarker for Post‐Hepatitis B Cirrhosis: A Clinical Value Study
Objective: This study aimed to assess the diagnostic value of soluble B7‐H6 (sB7‐H6) as a biomarker for post‐hepatitis B cirrhosis (LC) and to compare its performance with conventional non‐invasive biomarkers, including FIB‐4 and APRI. Methods: A prospective cohort study was conducted with 159 patients diagnosed with HBV‐related liver diseases, including 77 with chronic hepatitis B (CHB) and 82 with post‐hepatitis B cirrhosis (LC). Serum sB7‐H6 levels were quantified using enzyme‐linked immunosorbent assay (ELISA). The diagnostic performance of sB7‐H6 was evaluated through receiver operating characteristic (ROC) curve analysis. The diagnostic accuracy of sB7‐H6, both alone and in combination with FIB‐4, was compared to the traditional biomarkers APRI and FIB‐4. Results: Serum sB7‐H6 levels increased progressively with disease severity, with the highest levels observed in the LC group. The area under the ROC curve (AUC) for sB7‐H6 alone in diagnosing cirrhosis was 0.87, which was superior to both APRI (AUC = 0.75) and FIB‐4 (AUC = 0.79). The combined model of sB7‐H6 and FIB‐4 demonstrated improved diagnostic performance, achieving an AUC of 0.92, with sensitivity of 85.4% and specificity of 88.0%. Conclusion: Serum sB7‐H6 is a promising, non‐invasive biomarker for diagnosing post‐hepatitis B cirrhosis, outperforming traditional biomarkers such as FIB‐4 and APRI. The combined model of sB7‐H6 and FIB‐4 provides superior diagnostic accuracy and holds significant potential for clinical use in the early detection and risk stratification of liver cirrhosis in HBV‐infected patients.
- Open Access
- 31 January 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 503-510
Association between serum HBV DNA levels and liver fibrosis in chronic hepatitis B
- 31 January 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (4) , 503-510
Open AccessAssociation between serum HBV DNA levels and liver fibrosis in chronic hepatitis B
- Open Access
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784456
Correction: Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
- 16 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784456
Open AccessCorrection: Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
- 23 December 2025
- Published by Wiley in Liver International
- Vol. 46 (1) , e70491
Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease
Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is highly prevalent. Existing non‐invasive models for detecting fibrotic metabolic dysfunction‐associated steatohepatitis (MASH) perform poorly, partly due to discordant fibrosis‐inflammation relationships. We aimed to develop and validate a machine learning‐based stepwise strategy to improve identification of high‐risk MASLD ( F ≥ 2 + NAS ≥ 5). Methods: A multicenter retrospective cohort study analysed 840 biopsy‐proven MASLD patients (after quality control from 934) across eight centres. Logistic regression and multi‐omics detection identified predictors for significant fibrosis ( F ≥ 2) and definite MASH (NAS ≥ 5). Patients were divided into a training cohort and a validation cohort based on the centre. Eight machine learning algorithms were trained to diagnose five endpoints. Four diagnostic strategies were compared: fibrosis‐first ( F ≥ 2 then NAS ≥ 5), MASH‐first (NAS ≥ 5 then F ≥ 2), parallel (simultaneous F ≥ 2 and NAS ≥ 5), and single‐model (direct F ≥ 2 and NAS ≥ 5). Results: Both logistic regression and mass spectrometry data from this study demonstrated differences in fibrosis and NAS scores. Optimal models were: random forest (RF) for F ≥ 2, lightGBM for NAS ≥ 5, multilayer perceptron (MLP) for F ≥ 2 & NAS ≥ 5 and NAS ≥ 5| F ≥ 2, and elastic net for F ≥ 2|NAS ≥ 5. Internal validation showed the fibrosis‐first strategy achieved superior performance (accuracy 84.7%, specificity 87.0%, NPV 92.3%). External validation confirmed stepwise approaches outperformed the single‐model strategy. The sequential RF ( F ≥ 2) followed by MLP (NAS ≥ 5) approach demonstrated the highest clinical utility. Conclusions: A machine learning‐based stepwise diagnostic strategy, prioritising fibrosis assessment first, significantly improves identification of high‐risk MASLD ( F ≥ 2 + NAS ≥ 5). This validated approach enhances risk stratification accuracy, reduces reliance on biopsy, and offers strong clinical applicability for optimising management. Findings support integrating sequential AI diagnostics into clinical practice and future guidelines.
- 23 December 2025
- Published by Wiley in Liver International
- Vol. 46 (1) , e70491
Two‐Step Machine Learning Model Enhances Identification of High‐Risk Metabolic Dysfunction‐Associated Steatotic Liver Disease
Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is highly prevalent. Existing non‐invasive models for detecting fibrotic metabolic dysfunction‐associated steatohepatitis (MASH) perform poorly, partly due to discordant fibrosis‐inflammation relationships. We aimed to develop and validate a machine learning‐based stepwise strategy to improve identification of high‐risk MASLD ( F ≥ 2 + NAS ≥ 5). Methods: A multicenter retrospective cohort study analysed 840 biopsy‐proven MASLD patients (after quality control from 934) across eight centres. Logistic regression and multi‐omics detection identified predictors for significant fibrosis ( F ≥ 2) and definite MASH (NAS ≥ 5). Patients were divided into a training cohort and a validation cohort based on the centre. Eight machine learning algorithms were trained to diagnose five endpoints. Four diagnostic strategies were compared: fibrosis‐first ( F ≥ 2 then NAS ≥ 5), MASH‐first (NAS ≥ 5 then F ≥ 2), parallel (simultaneous F ≥ 2 and NAS ≥ 5), and single‐model (direct F ≥ 2 and NAS ≥ 5). Results: Both logistic regression and mass spectrometry data from this study demonstrated differences in fibrosis and NAS scores. Optimal models were: random forest (RF) for F ≥ 2, lightGBM for NAS ≥ 5, multilayer perceptron (MLP) for F ≥ 2 & NAS ≥ 5 and NAS ≥ 5| F ≥ 2, and elastic net for F ≥ 2|NAS ≥ 5. Internal validation showed the fibrosis‐first strategy achieved superior performance (accuracy 84.7%, specificity 87.0%, NPV 92.3%). External validation confirmed stepwise approaches outperformed the single‐model strategy. The sequential RF ( F ≥ 2) followed by MLP (NAS ≥ 5) approach demonstrated the highest clinical utility. Conclusions: A machine learning‐based stepwise diagnostic strategy, prioritising fibrosis assessment first, significantly improves identification of high‐risk MASLD ( F ≥ 2 + NAS ≥ 5). This validated approach enhances risk stratification accuracy, reduces reliance on biopsy, and offers strong clinical applicability for optimising management. Findings support integrating sequential AI diagnostics into clinical practice and future guidelines.
- 13 December 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 403-410
Clinical Characteristics of Indeterminate Chronic Hepatitis B Patients With and Without Liver Biopsy
Background: A substantial proportion of chronic hepatitis B (CHB) patients with indeterminate phase have significant liver injury, yet only a small proportion of these patients receive liver biopsy. We compared the clinical characteristics of indeterminate CHB patients with and without liver biopsy. Methods: A total of 2928 untreated CHB patients with indeterminate phases were retrospectively included. The indeterminate phase was identified and classified based on the AASLD 2018 guidance. Results: The median age of patients was 39.0 years and male accounted for 65.0%. A total of 288 (9.8%) CHB patients with the indeterminate phase underwent liver biopsy. Patients with liver biopsy were older (42.0 vs. 39.0 years, p < 0.001) and had higher HBV DNA (3.4 log 10 IU/mL vs. 2.7 log 10 IU/mL, p < 0.001), APRI (0.42 vs. 0.36, p < 0.001), FIB‐4 (1.18 vs. 0.99, p < 0.001), and liver stiffness values (9.9 vs. 6.6 kPa, p < 0.001), whereas lower platelets (169.0 × 10 9 /L vs. 192.0 × 10 9 /L, p < 0.001) than those without liver biopsy. Patients with PLT< 150.0 × 10 9 /L (OR 1.587, 95% CI 1.207–2.085, p < 0.001) and high HBV DNA (OR 1.458, 95% CI 1.298–1.637, p < 0.001) were more likely to receive liver biopsy in the indeterminate phase. Conclusion: Only 9.8% of indeterminate CHB patients underwent liver biopsy in our cohort. These patients exhibited higher values on noninvasive fibrosis tests. Hepatic histologic findings from biopsied patients should be interpreted with caution and should not be generalized to all patients in the indeterminate phase.
- 13 December 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 403-410
Clinical Characteristics of Indeterminate Chronic Hepatitis B Patients With and Without Liver Biopsy
Background: A substantial proportion of chronic hepatitis B (CHB) patients with indeterminate phase have significant liver injury, yet only a small proportion of these patients receive liver biopsy. We compared the clinical characteristics of indeterminate CHB patients with and without liver biopsy. Methods: A total of 2928 untreated CHB patients with indeterminate phases were retrospectively included. The indeterminate phase was identified and classified based on the AASLD 2018 guidance. Results: The median age of patients was 39.0 years and male accounted for 65.0%. A total of 288 (9.8%) CHB patients with the indeterminate phase underwent liver biopsy. Patients with liver biopsy were older (42.0 vs. 39.0 years, p < 0.001) and had higher HBV DNA (3.4 log 10 IU/mL vs. 2.7 log 10 IU/mL, p < 0.001), APRI (0.42 vs. 0.36, p < 0.001), FIB‐4 (1.18 vs. 0.99, p < 0.001), and liver stiffness values (9.9 vs. 6.6 kPa, p < 0.001), whereas lower platelets (169.0 × 10 9 /L vs. 192.0 × 10 9 /L, p < 0.001) than those without liver biopsy. Patients with PLT< 150.0 × 10 9 /L (OR 1.587, 95% CI 1.207–2.085, p < 0.001) and high HBV DNA (OR 1.458, 95% CI 1.298–1.637, p < 0.001) were more likely to receive liver biopsy in the indeterminate phase. Conclusion: Only 9.8% of indeterminate CHB patients underwent liver biopsy in our cohort. These patients exhibited higher values on noninvasive fibrosis tests. Hepatic histologic findings from biopsied patients should be interpreted with caution and should not be generalized to all patients in the indeterminate phase.
- Open Access
- 11 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1671149
Identification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
Background and aims: Hepatitis B virus (HBV) causes chronic hepatic infection, leading to various advanced liver diseases. Currently, there is still a lack of effective non-invasive biomarkers for evaluating hepatic inflammation and fibrosis. Circulating microRNAs (miRNAs) serve as key regulators and potential biomarkers in the progression and pathogenesis of HBV-associated progressive liver diseases. Here, we characterized the miRNA profile in chronic hepatitis B (CHB) patients and probed their association with liver inflammation and fibrosis. Approaches and results: We profiled 34 candidate miRNAs in serum from a well-characterized HBV Disease Continuum Cohort, comprising 165 individuals in the discovery set (42 healthy controls, HC; 40 CHB; 42 cirrhosis; 41 hepatocellular carcinomas, HCC) and 143 in an independent testing set. Serum miRNA levels were quantified by qRT-PCR. Supervised clustering and correlation analyses revealed distinct miRNA expression profiles across disease stages. Statistical analyses included logistic regression, and ROC/AUC evaluation with 5-fold cross-validation and external validation. Unsupervised clustering and correlation with histological G/S staging revealed stage-specific miRNA signatures: miR-224-5p, miR-125a-5p, and miR-15a-5p peaked in cirrhosis and strongly correlated with fibrosis stage (miR-224-5p: r = 0.606, p = 1.5E-12), while miR-200a-3p and miR-939-5p were predominantly upregulated in HCC. Critically, miR-224-5p emerged as a robust non-invasive biomarker for cirrhosis, with exceptional diagnostic accuracy (AUC = 0.973 in discovery; 0.906 in external validation), significantly outperforming APRI (0.803) and FIB-4 (0.809), and remained the sole independent predictor in multivariable analysis (p = 0.009). For HCC detection, the miR-200a-3p/AFP combined model achieved outstanding performance (AUC > 0.9), substantially improving upon AFP alone (0.737). Bioinformatic prediction of targets (297 for miR-224-5p; 616 for miR-200a-3p) highlighted associated in cancer- and senescence-related pathways; however, these associations are in silico and require experimental validation. Conclusion: We identify miR-224-5p as a fibroinflammatory activity indicator for early cirrhosis detection and miR-200a-3p as a synergistic enhancer of AFP for non-invasive HCC diagnosis, establishing a dual miRNA signature that spans the HBV disease continuum and addresses critical gaps in current risk stratification. These findings highlight the potential of specific serum miRNAs as non-invasive biomarkers for monitoring disease progression and improving the differential diagnosis during the process of HBV-related liver diseases.
- 11 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1671149
Open AccessIdentification of serum MicroRNAs associated with hepatic immunoinflammatory injury in chronic hepatitis B: implications for non-invasive diagnosis
Background and aims: Hepatitis B virus (HBV) causes chronic hepatic infection, leading to various advanced liver diseases. Currently, there is still a lack of effective non-invasive biomarkers for evaluating hepatic inflammation and fibrosis. Circulating microRNAs (miRNAs) serve as key regulators and potential biomarkers in the progression and pathogenesis of HBV-associated progressive liver diseases. Here, we characterized the miRNA profile in chronic hepatitis B (CHB) patients and probed their association with liver inflammation and fibrosis. Approaches and results: We profiled 34 candidate miRNAs in serum from a well-characterized HBV Disease Continuum Cohort, comprising 165 individuals in the discovery set (42 healthy controls, HC; 40 CHB; 42 cirrhosis; 41 hepatocellular carcinomas, HCC) and 143 in an independent testing set. Serum miRNA levels were quantified by qRT-PCR. Supervised clustering and correlation analyses revealed distinct miRNA expression profiles across disease stages. Statistical analyses included logistic regression, and ROC/AUC evaluation with 5-fold cross-validation and external validation. Unsupervised clustering and correlation with histological G/S staging revealed stage-specific miRNA signatures: miR-224-5p, miR-125a-5p, and miR-15a-5p peaked in cirrhosis and strongly correlated with fibrosis stage (miR-224-5p: r = 0.606, p = 1.5E-12), while miR-200a-3p and miR-939-5p were predominantly upregulated in HCC. Critically, miR-224-5p emerged as a robust non-invasive biomarker for cirrhosis, with exceptional diagnostic accuracy (AUC = 0.973 in discovery; 0.906 in external validation), significantly outperforming APRI (0.803) and FIB-4 (0.809), and remained the sole independent predictor in multivariable analysis (p = 0.009). For HCC detection, the miR-200a-3p/AFP combined model achieved outstanding performance (AUC > 0.9), substantially improving upon AFP alone (0.737). Bioinformatic prediction of targets (297 for miR-224-5p; 616 for miR-200a-3p) highlighted associated in cancer- and senescence-related pathways; however, these associations are in silico and require experimental validation. Conclusion: We identify miR-224-5p as a fibroinflammatory activity indicator for early cirrhosis detection and miR-200a-3p as a synergistic enhancer of AFP for non-invasive HCC diagnosis, establishing a dual miRNA signature that spans the HBV disease continuum and addresses critical gaps in current risk stratification. These findings highlight the potential of specific serum miRNAs as non-invasive biomarkers for monitoring disease progression and improving the differential diagnosis during the process of HBV-related liver diseases.